In a welcome move, Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.
IBD's proprietary RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the best-performing stocks tend to have an RS Rating of over 80 as they launch their largest climbs. See if Organon stock can continue to show renewed price strength and clear that threshold.
Looking For Winning Stocks? Try This Simple Routine
Is Organon Stock A Buy?
Organon stock reclaimed the 200-day moving average mid-February, a good sign. While now is not an ideal time to buy shares, see if the Organon stock goes on to establish and enter a buy zone in heavy trade.
The drug maker focused on women's heatlh saw both earnings and sales growth rise last quarter. Earnings-per-share increased from -34% to 9%. Revenue rose from -1% to 8%.
Organon stock holds the No. 12 rank among its peers in the Medical-Generic Drugs industry group. Teva Pharmaceutical ADR and ANI Pharmaceuticals are also among the group's highest-rated stocks.
